Results 31 to 40 of about 12,163 (174)
Physiological Reports, 2022 Chronic kidney disease (CKD) is an increasing and life‐threatening disease worldwide. Recent evidence indicates that blood coagulation factors promote renal dysfunction in CKD patients.
Lixin Fang +11 more
doaj +1 more source
Table1_Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation.DOCX
, 2021 Background and Purpose: Edoxaban exposure varies across different ethnicities. The purpose of our study was to examine the risk factors associated with high or low edoxaban concentrations in Asian populations.Methods: Participants with atrial ...
Shin-Yi Lin (225316) +6 more
core +1 more source
Edoxaban use in the context of dental procedures: analysis from the EMIT-AF/VTE database
BDJ Open, 2023 Introduction Literature reviews support continuing anticoagulation during dental procedures. However, studies often present grouped anticoagulation data, and information on individual anticoagulant management would be helpful to dentists.
Cathy Chen +9 more
doaj +1 more source
Journal of Arrhythmia, 2021 Background Nonadherence diminishes the efficacy of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (NVAF). This report presents the baseline survey results regarding medication adherence among NVAF patients who were ...
Tsuyoshi Shiga +11 more
doaj +1 more source
Frontiers in Physiology, 2018 Background: Non-vitamin K antagonist oral anticoagulants (NOACs) depend on some degree of renal excretion, and no head-to-head comparisons based on renal function is available. This study mainly investigated the trade-off property of NOACs in nonvalvular
Ling-Yun Zhou +6 more
doaj +1 more source
Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation
Clinical and Applied Thrombosis/Hemostasis, 2020 Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use. As the main adverse event is bleeding, it is relevant whether edoxaban has additional effects on platelet function. We aimed to assess
Juraj Sokol MD, PhD +8 more
doaj +1 more source
A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention. [PDF]
, 2015 Compared with the coronary setting, knowledge about antithrombotic therapies after endovascular treatment (EVT) is inadequate in patients with peripheral artery disease (PAD).
Grosso, Michael +13 more
core +1 more source
Scientific Reports, 2023 Since SLCO1B1 encodes the uptake transporter OATP1B1, which can influence the pharmacokinetic and pharmacodynamic profiles of edoxaban, polymorphisms in SLCO1B1 may affect the edoxaban response.
Ji Min Han +6 more
doaj +1 more source
, 2011 Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolic ...
Camm, A John +3 more
core +1 more source